ORIC’s Rinzimetostat Shows Potential for Best-in-Disease Efficacy and Safety in Prostate Cancer—Phase 3 Trial Set for 2026

Efficacy Metrics Outpace Standard-of-Care Therapies

ORIC Pharmaceuticals has revealed highly promising clinical data on its investigational PRC2 inhibitor, rinzimetostat, combined with darolutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-abiraterone. According to their latest Phase 1b data, the duo demonstrated landmark radiographic progression-free survival (rPFS) rates of 93% at 3 months, 84% at 4 months, and 84% at 5 months. These results put rinzimetostat’s performance ahead of several approved standard-of-care therapies for mCRPC, where 5-month landmark rPFS rates typically range from 60% to 75%.

Of note, 47% of patients achieved a PSA50 response—meaning at least a 50% drop in prostate-specific antigen levels—while 71% demonstrated a >50% reduction in circulating tumor DNA (ctDNA) among those tested. These improvements bolster the case for rinzimetostat’s potentially durable and meaningful clinical benefit.

Safety Profile Supports Long-Term Use and Adherence

Perhaps more striking than efficacy alone is the safety profile. At the 400 mg recommended Phase 3 dose (RP3D) of rinzimetostat, nearly all treatment-related adverse events (TRAEs) were low grade: 39% of patients experienced fatigue (split between Grade 1 and 2), and diarrhea and nausea were reported in 22% each (mainly Grade 1). Only one Grade 3 TRAE appeared, with no Grade 4 or 5 events attributed to the investigational combination. Dose modifications remained rare, with just one interruption and one discontinuation, and notably, no dose reductions required.

Higher doses (600 mg) didn’t deliver extra efficacy but brought more adverse events and dose adjustments, leading investigators to select 400 mg daily as the optimal regimen for Phase 3.

Phase 3 Pivotal Study Aims to Redefine Treatment Standards

ORIC is moving toward a global Phase 3 registrational trial—named Himalayas-1—in the first half of 2026. The study aims to enroll about 600 post-abiraterone mCRPC patients at more than 250 sites across 20+ countries. Participants will be randomized 1:1 to receive rinzimetostat (400 mg daily) plus darolutamide or physician’s choice of another androgen receptor inhibitor or chemotherapy. The primary endpoint is rPFS, with overall survival and patient-reported outcomes as key secondary measures.

This new regimen could fill a significant gap in the current treatment landscape, considering the estimated U.S. market alone includes about 17,000 eligible patients per year—a potential market exceeding $3.5 billion domestically and topping $7 billion globally.

Additional Data Show Promise Beyond the Core Cohort

Further analyses in other advanced prostate cancer populations (including those on alternative AR inhibitors) reveal similar durability with rPFS rates of 93%, 85%, and 85% at months 3, 4, and 5, respectively. Early food effect studies show no significant impact, indicating flexible dosing options and reinforcing the regimen’s usability.

Key Takeaway: Landmark Efficacy and Distinct Safety Profile Set Stage for Practice-Changing Potential

The recommended Phase 3 dose of rinzimetostat plus darolutamide stands out for delivering both high efficacy and low toxicity—a rare balance that could alter standards for mCRPC patients. As the Phase 3 Himalayas-1 trial prepares to launch, investors, clinicians, and patients alike will be watching closely for confirmation that this regimen can deliver on its "best-in-disease" promise.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI